[go: up one dir, main page]

MXPA02008064A - Combinacion novedosa de antihistaminas no sedantes que contienen sustancias las cuales influyen en la accion de leucotrienos, para tratar rinitis/conjuntivitis. - Google Patents

Combinacion novedosa de antihistaminas no sedantes que contienen sustancias las cuales influyen en la accion de leucotrienos, para tratar rinitis/conjuntivitis.

Info

Publication number
MXPA02008064A
MXPA02008064A MXPA02008064A MXPA02008064A MXPA02008064A MX PA02008064 A MXPA02008064 A MX PA02008064A MX PA02008064 A MXPA02008064 A MX PA02008064A MX PA02008064 A MXPA02008064 A MX PA02008064A MX PA02008064 A MXPA02008064 A MX PA02008064A
Authority
MX
Mexico
Prior art keywords
leukotriene
influence
action
novel combination
containing substances
Prior art date
Application number
MXPA02008064A
Other languages
English (en)
Inventor
Istvan Szelenyi
Original Assignee
Viatris Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh filed Critical Viatris Gmbh
Publication of MXPA02008064A publication Critical patent/MXPA02008064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invencion se refiere a una combinacion farmaceutica administrable topica u oralmente de una antihistamina no sedante, con excepcion de compuestos del tipo loratadina, y un antagonista de leucotrieno, seleccionado de un antagonista de leucotrieno D4, o un inhibidor de 5- Iipoxigenasa, o un antagonista de FLAP y opcionalmente soportes, extensores y agentes auxiliares convencionales, fisiologicamente inofensivos, para la profilaxis y tratamiento de rinitis alergica y/o vasomotora o conjuntivitis alergica.
MXPA02008064A 2000-02-17 2001-02-05 Combinacion novedosa de antihistaminas no sedantes que contienen sustancias las cuales influyen en la accion de leucotrienos, para tratar rinitis/conjuntivitis. MXPA02008064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10007203A DE10007203A1 (de) 2000-02-17 2000-02-17 Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis
PCT/EP2001/001190 WO2001060407A2 (de) 2000-02-17 2001-02-05 Neue kombination nichtsedierender antihistaminika mit substanzen, die die leukotrienwirkung beeinflussen, zur behandlung der rhinitis/konjunktivitis

Publications (1)

Publication Number Publication Date
MXPA02008064A true MXPA02008064A (es) 2004-04-05

Family

ID=7631276

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008064A MXPA02008064A (es) 2000-02-17 2001-02-05 Combinacion novedosa de antihistaminas no sedantes que contienen sustancias las cuales influyen en la accion de leucotrienos, para tratar rinitis/conjuntivitis.

Country Status (26)

Country Link
US (1) US6436924B2 (es)
EP (1) EP1265615B1 (es)
JP (1) JP5529362B2 (es)
KR (1) KR100764329B1 (es)
CN (1) CN1241569C (es)
AR (1) AR027528A1 (es)
AT (1) ATE287266T1 (es)
AU (1) AU781177B2 (es)
BR (1) BR0108445A (es)
CZ (1) CZ296395B6 (es)
DE (2) DE10007203A1 (es)
DK (1) DK1265615T3 (es)
ES (1) ES2236189T3 (es)
HU (1) HU228927B1 (es)
IL (2) IL151106A0 (es)
MX (1) MXPA02008064A (es)
NO (1) NO328153B1 (es)
NZ (1) NZ520470A (es)
PL (1) PL198357B1 (es)
PT (1) PT1265615E (es)
RU (1) RU2292208C2 (es)
SK (1) SK285990B6 (es)
TW (1) TWI296525B (es)
UA (1) UA72587C2 (es)
WO (1) WO2001060407A2 (es)
ZA (1) ZA200206575B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2373186A (en) * 2001-02-23 2002-09-18 Astrazeneca Ab Pharmaceutical combinations of a CCR3 antagonist and a compound which is usefulreatment of asthma, allergic disease or inflammation
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
AU2003264859A1 (en) * 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
JP2006508180A (ja) * 2002-10-17 2006-03-09 デコード ジェネティクス イーエッチエフ． 心筋梗塞に対する感受性遺伝子；治療の方法
US20080293750A1 (en) * 2002-10-17 2008-11-27 Anna Helgadottir Susceptibility Gene for Myocardial Infarction, Stroke, Paod and Methods of Treatment
US7851486B2 (en) 2002-10-17 2010-12-14 Decode Genetics Ehf. Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment
US7507531B2 (en) 2002-10-17 2009-03-24 Decode Genetics Chf. Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
WO2005027886A2 (en) * 2003-09-17 2005-03-31 Decode Genetics Ehf. Methods of preventing or treating recurrence of myocardial infarction
US20060019269A1 (en) * 2002-10-17 2006-01-26 Decode Genetics, Inc. Susceptibility gene for myocardial infarction, stroke, and PAOD, methods of treatment
US20040198743A1 (en) * 2003-01-31 2004-10-07 Schering Corporation Methods for treating allergic skin and allergic ocular conditions using combinations of histamine receptor antagonists
US20040235807A1 (en) * 2003-05-21 2004-11-25 Weinrich Karl P. Formulations including a topical decongestant and a topical corticosteroid suitable for nasal administration and method for treating obstructive sleep apnea
US20060263350A1 (en) * 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2005030331A1 (en) * 2003-09-26 2005-04-07 Fairfield Clinical Trials, Llc Combination antihistamine medication
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
US20100216863A1 (en) * 2004-01-30 2010-08-26 Decode Genetics Ehf. Susceptibility Gene for Myocardial Infarction, Stroke, and PAOD; Methods of Treatment
SI1713473T1 (sl) * 2004-02-06 2013-06-28 Meda Pharma Gmbh & Co. Kg Kombinacija antiholinergikov in glukokortikoidov za dolgotranjno zdravljenje astme in KOPB
PL1713471T3 (pl) * 2004-02-06 2012-06-29 Meda Pharma Gmbh & Co Kg Kombinacja środków antycholinergicznych i inhibitorów fosfodiesterazy typu 4 do leczenia chorób oddechowych
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
LT2522365T (lt) 2004-11-24 2017-02-10 Meda Pharmaceuticals Inc. Kompozicijos, apimančios azelastiną, ir jų panaudojimo būdai
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
CA2595791C (en) * 2005-03-16 2013-10-08 Meda Pharma Gmbh & Co. Kg The combination of anticholinergics and leukotriene receptor antagonists for the treatment of respiratory diseases
US7405302B2 (en) * 2005-10-11 2008-07-29 Amira Pharmaceuticals, Inc. 5-lipoxygenase-activating protein (FLAP) inhibitors
PL2098248T3 (pl) 2005-12-21 2012-11-30 Meda Pharma Gmbh & Co Kg Kombinacja antycholinergików, glukokortykoidów i beta2-agonistów do leczenia chorób zapalnych
WO2007126865A2 (en) * 2006-03-30 2007-11-08 Patrin Pharma Leukotriene antagonists via nasal drug delivery
WO2008067566A1 (en) 2006-11-30 2008-06-05 Amira Pharmaceuticals, Inc. Compositions and treatments comprising 5-lipoxygenase-activating protein inhibitors and nitric oxide modulators
EP2222299B1 (en) * 2007-11-19 2011-11-23 Bausch & Lomb Incorporated Use of levocabastine for modulating generation of pro-inflammatory cytokines
JP2012520880A (ja) * 2009-03-17 2012-09-10 アーシエックス セラピューティックス， インコーポレイテッド ケトチフェンの眼科用製剤および使用方法
MX2011009802A (es) 2009-03-17 2011-11-02 Aciex Therapeutics Inc Formulaciones oftalmicas de cetirizina y metodos de uso.
US8569273B2 (en) 2009-03-17 2013-10-29 Aciex Therapeutics, Inc. Ophthalmic formulations of cetirizine and methods of use
SG175390A1 (en) 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
KR101418404B1 (ko) * 2012-01-06 2014-07-10 한미약품 주식회사 레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
WO2014160440A1 (en) 2013-03-13 2014-10-02 Flatley Discovery Lab Pyridazinone compounds and methods for the treatment of cystic fibrosis
ES2745041T3 (es) 2013-03-13 2020-02-27 Inflammatory Response Res Inc Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunitarios
KR101555908B1 (ko) * 2013-12-19 2015-09-25 한미약품 주식회사 몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
DK3102209T3 (da) 2014-02-04 2021-07-12 Bioscience Pharma Partners Llc Anvendelse af flap-hæmmere til at reducere neuroinflammationsmedieret læsion i centralnervesystemet
WO2016044095A1 (en) 2014-09-15 2016-03-24 Inflammatory Response Research, Inc. Levocetirizine and montelukast in the treatment of inflammation mediated conditions
CA3126021A1 (en) * 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
US12257172B2 (en) 2019-02-28 2025-03-25 Coloplast A/S Sensor patch for attachment to a base plate
CN110721189A (zh) * 2019-11-19 2020-01-24 贵州云峰药业有限公司 一种皮肤消毒剂
CA3166799A1 (en) 2020-02-03 2021-08-12 Vered Rosenberger Topical montelukast formulations
US12233055B2 (en) 2020-02-03 2025-02-25 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
CN116284470B (zh) * 2023-02-15 2024-08-02 广西中医药大学 一种海蛇尾多糖硫酸酯衍生物的制备方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3813384A (en) 1972-01-17 1974-05-28 Asta Werke Ag Chem Fab Basically substituted benzyl phthalazone derivatives,acid salts thereof and process for the production thereof
ATE84968T1 (de) 1987-11-13 1993-02-15 Asta Medica Ag Azelastin enthaltende arzneimittel zur anwendung in der nase und/oder am auge.
WO1989010143A1 (en) * 1988-04-27 1989-11-02 Schering Corporation Certain paf antagonist antihistamine combinations and methods
US5276044A (en) * 1991-08-14 1994-01-04 Allergan, Inc. Leukotriene receptor antagonist and antihistamine complex pharmaceutical compositions
PT815860E (pt) * 1992-08-03 2006-08-31 Sepracor Inc Carboxilato de terfenadina e tratamento de desordens alergicas.
CA2245162A1 (en) * 1996-02-08 1997-08-14 Merck & Co., Inc. Method of treatment and pharmaceutical composition
DE19610882A1 (de) * 1996-03-20 1997-09-25 Dresden Arzneimittel Neue 1,3,5-trisubstituierte Indazol-Derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender Wirkung, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5900421A (en) * 1997-02-11 1999-05-04 Sepracor Inc. Methods and compositions for treating allergic asthma and dermatitis using descarboethoxyloratadine
IL131492A0 (en) * 1997-04-30 2001-01-28 Warner Lambert Co Topical nasal antiinflammatory compositions
US6242179B1 (en) 1997-12-17 2001-06-05 Incyte Pharmaceuticals, Inc. Human phosphatases
SK286103B6 (sk) * 1997-12-23 2008-03-05 Schering Corporation Farmaceutický prostriedok na liečenie respiračných a kožných ochorení s obsahom aspoň jedného antagonistu leukotriénu a aspoň jedného antihistaminikaa jeho použitie
US6194431B1 (en) * 1998-04-14 2001-02-27 Paul D. Rubin Methods and compositions using terfenadine metabolites in combination with leukotriene inhibitors

Also Published As

Publication number Publication date
DK1265615T3 (da) 2005-05-30
RU2292208C2 (ru) 2007-01-27
PL198357B1 (pl) 2008-06-30
EP1265615A2 (de) 2002-12-18
AR027528A1 (es) 2003-04-02
AU4058401A (en) 2001-08-27
ZA200206575B (en) 2003-05-14
KR20020083161A (ko) 2002-11-01
HU228927B1 (en) 2013-06-28
NZ520470A (en) 2004-05-28
NO328153B1 (no) 2009-12-21
CN1241569C (zh) 2006-02-15
UA72587C2 (uk) 2005-03-15
TWI296525B (en) 2008-05-11
EP1265615B1 (de) 2005-01-19
CZ296395B6 (cs) 2006-03-15
WO2001060407A2 (de) 2001-08-23
BR0108445A (pt) 2003-04-01
IL151106A0 (en) 2003-04-10
CZ20022700A3 (cs) 2002-11-13
WO2001060407A3 (de) 2002-03-07
JP5529362B2 (ja) 2014-06-25
PT1265615E (pt) 2005-05-31
ES2236189T3 (es) 2005-07-16
HUP0204079A2 (hu) 2003-04-28
NO20023818D0 (no) 2002-08-12
PL355818A1 (en) 2004-05-17
SK11752002A3 (sk) 2002-11-06
DE10007203A1 (de) 2001-08-23
DE50105126D1 (de) 2005-02-24
RU2002123345A (ru) 2004-03-20
US6436924B2 (en) 2002-08-20
AU781177B2 (en) 2005-05-12
JP2003522803A (ja) 2003-07-29
IL151106A (en) 2008-06-05
KR100764329B1 (ko) 2007-10-05
SK285990B6 (sk) 2008-01-07
NO20023818L (no) 2002-08-12
ATE287266T1 (de) 2005-02-15
HK1053792A1 (en) 2003-11-07
CN1400903A (zh) 2003-03-05
US20010025040A1 (en) 2001-09-27
HUP0204079A3 (en) 2006-07-28

Similar Documents

Publication Publication Date Title
MXPA02008064A (es) Combinacion novedosa de antihistaminas no sedantes que contienen sustancias las cuales influyen en la accion de leucotrienos, para tratar rinitis/conjuntivitis.
UY24543A1 (es) Sal mesilato trihidrato de 5-(2-(4-(1,2-benzoisotiazol- 3-il)-1-piperazinil)etil)-6-cloro-1,3-dihidro-2h-indol-2-ona
NO20081843L (no) Farmasoytisk sammensetning for forbedret kognitiv funksjon
DE60214198D1 (de) Isoxazolyl-pyrimidines als inhibitoren von src- und lck-protein-kinasen
NO20070247L (no) Amino-5,5-difenylimidazolonderivater for inhibisjon av beta-sekretase
MY119997A (en) Mesylate dihydrate salts of 5-(2-(4-(1, 2-benzisothiazol-3-yl) -1-piperazinyl)-6-chloro-1, 3- dihydro-2h-indol-2-one
NO20052739L (no) CCR5-antagonister som medikamenter
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
NO20011721L (no) N-aralkylaminotetraliner som ligander for neuropeptid Y Y5- reseptoren
ATE368031T1 (de) Neue gamma secretase inhibitoren
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
DE60322423D1 (de) Pyrrolidin- und azetidinverbindungen alsccr5-antagonisten
MXPA04002825A (es) Derivados de quinolina como antagonistas de neuropeptido y.
DE60324014D1 (de) Heterocyclische verbindungen alsccr5-antagonisten
MEP54608A (en) Arylmethylamine derivatives for use as tryptase inhibitors
NO20060328L (no) Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser
NO20034301L (no) Cyano-substituerte dihydropyrimidin forbindelser
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
PT1206444E (pt) Compostos que inibem a actividade da triptase
PH12022551418A1 (en) Compounds for treatment of alzheimer`s disease
NO20012310D0 (no) Optisk aktiv pyridyl-4H-1,2,4-oksazdiazinderivat og dets anvendelse ved behandling av karsykdommer
CA2410554A1 (en) Use of (+)-.alpha. -(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis
MX9701116A (es) Profarmacos de 5-(2-[4-(1,2-benzoisotiazol-3-il)-1-piperazinil]etil)-6-clor o-1,3-dihidro-2h-indol-2-ona.
NO20044550L (no) Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer
ATE400563T1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel

Legal Events

Date Code Title Description
FG Grant or registration
HC Change of company name or juridical status